A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity.

ACE2 binding BA.2.65 SARS-CoV-2 antigenic escape coronavirus receptor binding virus evolution virus structure

Journal

Cell reports. Medicine

ISSN: 2666-3791

Titre abrégé: Cell Rep Med

Pays: United States

ID NLM: 101766894

Informations de publication

Date de publication:
02 May 2024

Historique:

received: 06 10 2023

revised: 10 01 2024

accepted: 11 04 2024

medline: 10 5 2024

pubmed: 10 5 2024

entrez: 9 5 2024

Statut: aheadofprint

Résumé

BA.2.86, a recently described sublineage of SARS-CoV-2 Omicron, contains many mutations in the spike gene. It appears to have originated from BA.2 and is distinct from the XBB variants responsible for many infections in 2023. The global spread and plethora of mutations in BA.2.86 has caused concern that it may possess greater immune-evasive potential, leading to a new wave of infection. Here, we examine the ability of BA.2.86 to evade the antibody response to infection using a panel of vaccinated or naturally infected sera and find that it shows marginally less immune evasion than XBB.1.5. We locate BA.2.86 in the antigenic landscape of recent variants and look at its ability to escape panels of potent monoclonal antibodies generated against contemporary SARS-CoV-2 infections. We demonstrate, and provide a structural explanation for, increased affinity of BA.2.86 to ACE2, which may increase transmissibility.

Identifiants

DOI: 10.1016/j.xcrm.2024.101553 PMID: 38723626

pubmed: 38723626

pii: S2666-3791(24)00245-3

doi: 10.1016/j.xcrm.2024.101553

pii:

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101553

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests G.R.S. sits on the GSK Vaccines Scientific Advisory Board, consults for AstraZeneca, and is a founder member of RQ Biotechnology. D.I.S. consults for AstraZeneca. Oxford University holds intellectual property related to SARS-CoV-2 mAbs discovered in G.R.S.’s laboratory. S.J.D. is a scientific advisor to the Scottish Parliament on COVID-19.

Auteurs

Chang Liu (C)

Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Daming Zhou (D)

Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, Centre for Human Genetics, Oxford, UK.

Aiste Dijokaite-Guraliuc (A)

Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Piyada Supasa (P)

Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.

Helen M E Duyvesteyn (HME)

Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, Centre for Human Genetics, Oxford, UK.

Helen M Ginn (HM)

Centre for Free Electron Laser Science, Hamburg, Germany.

Muneeswaran Selvaraj (M)

Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.

Alexander J Mentzer (AJ)

Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Raksha Das (R)

Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.

Thushan I de Silva (TI)

Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Thomas G Ritter (TG)

NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Megan Plowright (M)

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Thomas A H Newman (TAH)

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Lizzie Stafford (L)

NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Barbara Kronsteiner (B)

NDM Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.

Nigel Temperton (N)

Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and University of Greenwich Chatham Maritime, Kent ME4 4TB, UK.

Yuan Lui (Y)

Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.

Martin Fellermeyer (M)

Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.

Philip Goulder (P)

Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK; Department of Paediatrics, University of Oxford, Oxford, UK.

Paul Klenerman (P)

NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK; Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Susanna J Dunachie (SJ)

NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NDM Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand.

Michael I Barton (MI)

Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.

Mikhail A Kutuzov (MA)

Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.

Omer Dushek (O)

Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.

Elizabeth E Fry (EE)

Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, Centre for Human Genetics, Oxford, UK. Electronic address: liz@strubi.ox.ac.uk.

Juthathip Mongkolsapaya (J)

Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand. Electronic address: juthathip.mongkolsapaya@well.ox.ac.uk.

Jingshan Ren (J)

Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, Centre for Human Genetics, Oxford, UK. Electronic address: ren@strubi.ox.ac.uk.

David I Stuart (DI)

Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, Centre for Human Genetics, Oxford, UK; Sir William Dunn School of Pathology, Oxford, UK. Electronic address: dave@strubi.ox.ac.uk.

Gavin R Screaton (GR)

Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: gavin.screaton@medsci.ox.ac.uk.

Classifications MeSH